Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IL-10–producing and naturally occurring CD4+ Tregs: limiting collateral damage
Anne O’Garra, Pedro L. Vieira, Paulo Vieira, Anne E. Goldfeld
Anne O’Garra, Pedro L. Vieira, Paulo Vieira, Anne E. Goldfeld
View: Text | PDF
Review Series

IL-10–producing and naturally occurring CD4+ Tregs: limiting collateral damage

  • Text
  • PDF
Abstract

Effective immune responses against pathogens are sometimes accompanied by strong inflammatory reactions. To minimize damage to self, the activation of the immune system also triggers anti-inflammatory circuits. Both inflammatory and anti-inflammatory reactions are normal components of the same immune response, which coordinately fight infections while preventing immune pathology. IL-10 is an important suppressive cytokine, produced by a large number of immune cells in addition to the antigen-driven IL-10–producing regulatory and the naturally occurring suppressor CD4+ T cells, which is a key player in anti-inflammatory immune responses. However, additional mechanisms have evolved to ensure that pathogen eradication is achieved with minimum damage to the host. Here we discuss those mechanisms that operate to regulate effector immune responses.

Authors

Anne O’Garra, Pedro L. Vieira, Paulo Vieira, Anne E. Goldfeld

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Layers of regulation of the immune response. At low levels of inflammati...
Layers of regulation of the immune response. At low levels of inflammation (A) both Foxp3+ naturally occurring Tregs and Foxp3– IL-10 Tregs inhibit CD4+ T cell proliferation through IL-10–independent, cell contact–dependent mechanisms. (B) Similar mechanisms may control immune responses to self antigens and autoimmune pathologies associated with low-level inflammation such as gastritis. (C) When strong inflammation occurs, with activation of APCs, effector molecules, such as IL-10 and TGF-β, secreted by Tregs are required to control CD4+ T cell responses. TLR, Toll-like receptor.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts